How are energy investors positioned?
Bone Biologics Corporation (NASDAQ:BBLG) has filed an update to its prospectus supplement, detailing changes to the terms of its existing At The Market (ATM) offering agreement with H.C. Wainwright & Co., LLC, originally dated September 27, 2024. The amendment, filed today, adjusts the maximum amount of shares the company can offer to $832,009.
The revision comes after the company previously sold approximately $846,288 worth of common stock under the same Sales Agreement, as stated in the prior prospectus supplement dated September 27, 2024. The legal opinion regarding the legality of the shares issuable under the Sales Agreement and covered by the updated prospectus supplement has been included as Exhibit 5.1 in the filing.
Bone Biologics, based in Burlington (NYSE:BURL), MA, operates within the orthopedic, prosthetic, and surgical appliances and supplies industry, as classified under the Standard Industrial Classification code 3842. The company is incorporated in Delaware and ends its fiscal year on December 31.
The SEC filing also includes the consent of Harter Secrest & Emery LLP, the legal firm that provided the opinion, and an interactive data file for the cover page, which is embedded within the Inline XBRL document.
This adjustment to the ATM offering agreement enables Bone Biologics to continue raising capital through the sale of its common stock on the Nasdaq Capital Market. The company's securities, including common stock and warrants to purchase common stock, are listed under the trading symbols BBLG and BBLGW, respectively.
In other recent news, Bone Biologics Corp has experienced significant changes in its leadership and financial operations. The company announced the resignation of board member Don Hankey, emphasizing that his departure was not due to disagreements on operations, policies, or practices. The company has not yet announced plans to fill the vacated board seat.
During the Annual Meeting of Stockholders, four director nominees were elected, namely Bruce Stroever, Siddhesh Angle, Robert Gagnon, and the now-resigned Don Hankey. The stockholders also approved executive compensation and ratified Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
In terms of financial operations, Bone Biologics has finalized an agreement concerning the exercise of existing warrants for the acquisition of its common stock. Approximately 781,251 common shares will be acquired at $2.43 each from the exercised warrants initially issued in March 2024.
The company is also issuing new unregistered warrants for an additional 1,562,502 shares of common stock, immediately exercisable at $2.00 per share. The exclusive placement agent for this offering is H.C. Wainwright & Co., and the transaction is expected to generate around $2.1 million in gross proceeds.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.